Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Sees Large Growth in Short Interest

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 18,610 shares, an increase of 71.8% from the December 15th total of 10,835 shares. Based on an average daily volume of 55,559 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 55,559 shares, the short-interest ratio is currently 0.3 days.

Algernon Pharmaceuticals Price Performance

Shares of OTCMKTS:AGNPF opened at $0.04 on Thursday. Algernon Pharmaceuticals has a 12-month low of $0.03 and a 12-month high of $0.09. The business has a 50-day moving average price of $0.05 and a 200 day moving average price of $0.05.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).